4D Molecular Therapeutics, Inc. (FDMT)

14.97USD +1.84% (+0.27)

Over 1M: +39.3%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

12 14 16
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 90K Q3 '25 — Operating Cash Flow: -46.5M Q3 '25 — Free Cash Flow: -46.6M Q3 '25 — Net Income: -56.9M Q4 '25 — Revenue: 85.1M Q4 '25 — Operating Cash Flow: 28.6M Q4 '25 — Free Cash Flow: 28.5M Q4 '25 — Net Income: 19.4M Q1 '26 — Revenue: 3M Q1 '26 — Operating Cash Flow: -68.1M Q1 '26 — Net Income: -68.8M Q2 '26 — Revenue: 3.8M Q2 '26 — Operating Cash Flow: -70M Q2 '26 — Net Income: -72.9M -70M -35M 0 35M 70M 105M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.8
SBC / sales 22.2%
OE margin -192.4%
Oper. margin -214.2%
ROIC -236.3%
Accruals -4.7%
EBITDA margin -208.8%
FCF margin -170.2%
OCF margin -169.6%
Profit margin -194.7%
ROA -36.4%
ROCE -44.3%
ROE -44.0%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.5
EV/Sales 5.3×
EV/OE -2.7×
P/C 2.3×
P/B 2.0×
FCF yield -18.9%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales 0.0039×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.5
ND/EBITDA 0.7
Cash runway 2.2 yr
Cash / Debt 18.4×
Debt / Eq 0.048×
Debt payback 0.0 yr
Quick ratio 8.0×
F-score 3.9 pts
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

9.1
Sales/sh Y/Y +259513.1%
Sales CAGR 4Y +47.4%
Sales Q/Q +25106.7%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.